Genix Pharmaceuticals Corporation
Genix Pharmaceuticals Corporation formulates, manufactures, licenses, and markets life sciences related products with focus on nutraceuticals and pharmaceuticals in Canada. The company develops Flu-X, an anti-viral, anti-flu, and common colds coronavirus oral and spray herbal product; Renochlor, a dietary supplement to support kidney health; and Sucanon, a herbal health supplement to manage blood… Read more
Genix Pharmaceuticals Corporation (GENPF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of January 2025: 0.049x
Based on the latest financial reports, Genix Pharmaceuticals Corporation (GENPF) has a cash flow conversion efficiency ratio of 0.049x as of January 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-63.10K) by net assets ($-1.29 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Genix Pharmaceuticals Corporation - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Genix Pharmaceuticals Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Genix Pharmaceuticals Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genix Pharmaceuticals Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TronicS Microsystems SA
PA:ALTRO
|
-0.435x |
|
Capitol Nusantara Indonesia
JK:CANI
|
0.005x |
|
VIP Gloves Ltd
AU:VIP
|
-0.003x |
|
Aben Gold Corp.
F:ML1
|
-0.009x |
|
Retail Food Group Limited
PINK:RFGPF
|
0.000x |
|
CohBar Inc
NASDAQ:CWBR
|
-0.190x |
|
BAINS MER MONAC N
MU:RJ8
|
N/A |
|
Australian Pacific Coal Ltd
AU:AQC
|
2.588x |
Annual Cash Flow Conversion Efficiency for Genix Pharmaceuticals Corporation (2017–2024)
The table below shows the annual cash flow conversion efficiency of Genix Pharmaceuticals Corporation from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-10-31 | $-1.18 Million | $-187.34K | 0.158x | -18.39% |
| 2023-10-31 | $-1.14 Million | $-220.67K | 0.194x | +382.67% |
| 2022-10-31 | $3.20 Million | $-219.58K | -0.069x | +35.67% |
| 2021-10-31 | $4.01 Million | $-428.31K | -0.107x | -165.74% |
| 2020-10-31 | $4.86 Million | $-195.03K | -0.040x | -102.89% |
| 2019-10-31 | $-42.13K | $-58.55K | 1.390x | +398.33% |
| 2018-10-31 | $122.57K | $34.18K | 0.279x | +460.73% |
| 2017-10-31 | $120.97K | $-9.35K | -0.077x | -- |